In this study the role of circulating transforming growth factor ␤1 (TGF␤1) on progression of renal hypertensive disease has been investigated. Fifty consecutive outpatients with essential hypertension were enrolled and divided into three groups, according to their urinary albumin excretion (UAE). Group A comprised 10 hypertensives with UAE р20 mg/24 h (normoalbuminuric group); Group B included 21 hypertensives with UAE Ͼ 20 Ͻ 300 mg/24 h (microalbuminuric group); Group C encompassed 19 hypertensives with UAE у 300 mg/24 h (proteinuric group). In all patients UAE by immunonephelometric assay, circulating TGF␤1 by a solid phase specific sandwich ELISA technique, BUN and creatinine by routine laboratory methods were determined. In addition, left ventricular telediastolic internal diameter, interventricular septum diastolic (IVSTd), posterior wall thickness, total and normalised to height 2.7 left ventricular mass, relative wall thickness and left ventricular ejection fraction by M-B Mode echocardiography were
Introduction
Hypertension represents a common and powerful predisposing factor for cardiovascular disease or events and renal failure. 1 Approximately 90% of patients with end-stage renal disease (ESRD) have a history of hypertension. High blood pressure may initiate renal damage and also increase the rate of progression of renal insufficiency. 2 Persistent high blood pressure represents the early trigger mechanism for renal disease. The incidence of hypertension nephropathy, which can be defined as renal insufficiency in which hypertension is the only recognised aetiologic factor, is difficult to quantify. It is well known that the natural course of hyperten- calculated. Our results indicated that TGF␤1 levels were significantly (P Ͻ 0.05) higher in Group B and C than Group A and in Group C than Group B. In addition IVSTd values were significantly (P Ͻ 0.05) higher in both Group B and C than Group A. An evident, but not significant, higher prevalence of subjects with left ventricular hypertrophy were observed in Group C as compared with other groups. In all hypertensive subjects TGF␤1 correlated directly with UAE (P Ͻ 0.0001) but not with BMI, LVM/h 2.7 and mean blood pressure. Our data indicated that TGF␤1 might be considered a useful marker to evaluate the severity and progression of hypertensive renal disease. Additional long-term clinical data are needed to evaluate whether inhibition of TGF␤1 system may prolong the time to the ESRD in hypertensive patients. sion is characterised by a progressive impairment of renal function related to the age of patients and severity of disease. 3 Additionally in diabetic and hypertensive subjects, there are several data that indicate a relationship between amounts of urinary albumin and risk of progression kidney disease. 4 The final pathway is represented by progressive sclerosis of glomeruli. A main role is played by transforming growth factor ␤1 (TGF␤1), a multifunctional cytokine that regulates cell growth, differentiation, matrix production, 5 blocks matrix degradation 6 inducing fibrosis in many tissues, including kidney, blood vessels, lung and heart. 7 Data from experimental studies seem to indicate that high circulating levels of TGF␤1 can mediate renal fibrosis and loss of function. 8 Only few clinical studies have been designed to evaluate the role of TGF␤1 in human hypertension. [9] [10] [11] [12] Accordingly, the aim of the present study is to evaluate the relationship between circulating TGF␤1 and progression of renal damage in a population of hypertensive subjects.
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Patients and methods
Patients
Fifty consecutive outpatients were enrolled (30 males and 20 females, aged 43 to 70 years). The patients were attending the antihypertensive centre of the Department of Internal Medicine at the University of Palermo (Italy). Subjects were included when blood pressure (average of three determinations) was greater than 140/90 mm Hg on at least two occasions when the patients were off medication. 13 Records of patients taking antihypertensive drugs were reviewed to ascertain the validity of the diagnosis of hypertension and patients were included if blood pressure had been greater than 140/90 mm Hg on two occasions, before treatment. Systolic (SBP) and diastolic blood pressure (DBP) and mean arterial pressure (MAP) were taken. MAP was calculated from the equation
Exclusion criteria included secondary hypertension, diabetes mellitus, cardiovascular diseases (defined as myocardial infarction, recent stroke within 6 months, heart failure etc), endocrinal diseases, severe chronic renal failure, alcoholism and psychiatric problems. In all subjects the urinary albumin excretion (UAE) was determined and according to this measurement patients were classified into the following groups:
• Group A (normoalbuminuric hypertensives):
encompassed 10 hypertensive patients with UAE р20 mg/24 h; • Group B (microalbuminuric hypertensives):
included 21 hypertensive patients with UAE Ͼ20 Ͻ 300 mg/24 h; • Group C (proteinuric hypertensives): comprised 19 hypertensive patients with UAE у300 mg/24 h.
Methods
Each patient gave informed consent after receiving a detailed description of the study procedure. The study was approved by the Ethics Committee of our institution. Patients underwent a general analytical laboratory parameters profile including BUN, creatinine, glycaemia, electrolytes (serum sodium, potassium, chloride), by routine laboratory methods.
Urinary albumin excretion
To eliminate the intra-individual day-to-day variability of UAE, three consecutive 24-h urine collections were used. In addition, to assess the completeness of a 24-h urine collection, measurements of urinary rate of clearance of creatinine were evaluated. UAE was measured by immunonephelometric assay (Bohering Institute; limit of detection, 0.1 mg/dl; inter-assay coefficient 3.5%). Microalbuminuria was defined as a level of UAE у20 and Ͻ300 mg/24 h.
TGF␤1
Peripheral venous blood was obtained from each patient and the sera were isolated and stored at −70°C. TGF␤1 levels were determined by using a solid-phase specific sandwich (R&D Systems Minneapolis, MN, USA) ELISA technique as previously described. 14 The interassay and intra-assay variations for determining TGF␤1 were 8% and 6% respectively. The sensitivity, hence minimum level of detection of TGF␤1 by sandwich ELISA, was 5 pg/ml.
Echocardiography parameters
All hypertensive patients underwent an echocardiography examination M and B Mode using computerised echocardiography (ESAOTE, Italy) for the determination of the following parameters: left ventricular telediastolic internal diameter (LVIDd), interventricular septum diastolic (IVSTd), posterior wall thickness (PWTd), total left ventricular mass (LVM) normalised to height 2.7 (LVM/h 2.7 ). [15] [16] [17] [18] The relative wall thickness (RWT) using the formula [(PWTd/LVIDd)×2] was also calculated. Ejection fraction from left ventricular end-diastolic and endsystolic volumes was measured from the apical fourchamber view, using the ellipsoidal single-plane algorithm. 19 Mean ejection fraction was automatically calculated by the echocardiographic processing system. In our laboratory the ejection fraction calculated over five consecutive beats permitted optimal reproducibility and accuracy. 20 The presence of left ventricular hypertrophy (LVH) was established when LVM/h 2.7 was Ͼ51 g/m 2.7 for male and female patients.
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Statistical analysis
Differences among three groups were analysed by one-way analysis of variance and the post-hoc Newman-Keuls test. Since an asymmetry of TGF␤1 data distribution was evident (high skewness), the difference in TGF␤1 values among the groups were analysed by a non-parametric test, ie, Mann-Whitney U test. Differences among hypertrophic patients' prevalence of three groups were analysed by z-test. Relationship among TGF␤1 and the other parameters were analysed by non-parametric linear regression with Kendall's rank correlation coefficient and multiple regression analysis. Independent variables in multiple regression analysis were age, BMI, LVM/h 2.7 and MBP. Data are expressed as mean value ± s.d. A P Ͻ 0.05 was considered statistically significant.
Results
Our results are summarised in the tables and figures. All the hypertensive groups were comparable with regard to sex and age. UAE levels were obviously significantly (P Ͻ 0.05) higher in proteinuric than microalbuminuric and normoalbuminuric, and in microalbuminuric than normalbuminuric hypertensive subjects. BUN and creatinine levels were significantly (P Ͻ 0.05) higher in both microalbuminuric and proteinuric than normalbuminuric hypertensive subjects. TGF␤1 levels were significantly (P Ͻ 0.05) higher in proteinuric and microalbuminuric hypertensives than those detectable in normoalbuminuric and proteinuric in respect to microalbuminuric hypertensive subjects (Table 1) .
Cardiac parameters
ISVTd levels were significantly (P Ͻ 0.05) higher in both microalbuminuric and proteinuric than normoalbuminuric hypertensive subjects. An evident, but not significant, higher prevalence of subjects with LVH were observed in proteinuric hypertensive subjects with respect to both microalbuminuric and normoalbuminuric hypertensive subjects. No significant change in the remaining cardiac parameters were observed among the three groups ( Table  2) . To evaluate the impact of LVH on TGF␤1 levels, all the hypertensive subjects were also subdivided according to the presence or the absence of LVH. No significant change in TGF␤1 values between LVH hypertensives and non-LVH hypertensives (6.7 ± 5.1 vs 5.3 ± 3.7 ng/ml) was observed.
Correlations
In all hypertensive subjects TGF␤1 correlated directly with UAE (P Ͻ 0.0001) but not with BMI, LVM/h 2.7 and MBP ( Figure 1 ). Multiple regression analysis indicates that this relation also remains sig- a Mann-Whitney Utest. BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; MBP = mean blood pressure; BUN = blood urea nitrogen; UAE = urinary albumin excretion; TGF␤1 = transforming growth factor ␤1. ; %LVH = percentage of subjects with left ventricular hypertrophy. 
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Discussion and conclusion
Our data indicate that in hypertensive patients there is a strong relationship between progressive increase of TGF␤1 levels and progression of renal damage, evaluated by albumin excretion rate. On the contrary no relationship between TGF␤1, BMI, blood pressure and LVM/h 2.7 has been found. Overproduction of TGF␤1 has been experimentally linked to the sequela of chronic hypertension, including vascular remodelling and progressive renal disease. 11, 22 Moreover experimental data have also demonstrated that high circulating levels of this cytokine can mediate organ and tissue damage. 23, 24 The exact mechanism by which TGF␤1 activity is enhanced in hypertensive renal disease is not yet clear, but an overproduction of TGF␤1 has been reported to be mediated by angiotensin II. 25 According to Remuzzi and Bertani 26 the overproduction in synthesis of angiotensin II by the kidney as a result of injury leads to an increase in the expression of the gene for TGF␤1 in tubular cells, increasing the synthesis of type IV collagen-determining fibrosis. Our finding may indicate that in hypertensive patients an excess of circulating levels of TGF␤1 is associated with albumin excretion rate, adding clinical supports to the notion that it plays a role in the pathophysiology of end-organ damage. This fact is also supported by the direct relationship between TGF␤1 levels and one of the most important measurements of progressive renal damage such as albumin excretion rate. In our opinion, it is possible to hypothesise that TGF␤1-overproduction may be considered a pathogenetic mechanism for the excess burden of hypertension and hypertensive renal damage. In this area some experimental and clinical data suggest a role for TGF␤1 in the increase of blood pressure. 10, 25 However, no relationship between TGF␤1 and MBP was observed in our study. Thus according to recent data from Laviades et al, 9 nonhaemodynamic mechanisms may be involved in the potential contribution of this growth factor to microalbuminuria or proteinuria in hypertension. The biological actions of TGF␤1 and the reported association with renal pathology support the hypothesis that increased frequency of TGF␤1-overproduction is a candidate mechanism for progression of hypertensive renal disease to end-stage renal disease. 11 In view of this, it has been recently reported that some antihypertensive drugs such as angiotensinconverting enzyme (ACE) inhibitors decrease TGF␤1 levels, and that changes in TGF␤1 values may predict the course of diabetes nephropathy. 27 Accordingly, it should be possible to select a subset of hypertensive subjects (with higher levels of TGF␤1) who are more responsive to the treatment and characterised by a possible slow progression of renal disease.
Our study shows the lack of relationship between TGF␤1 and left ventricular structure and function, that might be in contrast with some recent data. 9, 28, 29 This may be explained by the selection criteria utilised by us. In fact, we have gone in the direction of analysing, the role of TGF␤1 on renal damage in hypertensives and have selected the subjects according to their albumin excretion rate and not according to their left ventricular mass values. In addition, all the hypertensive subjects were previously treated and it is well known that antihypertensive therapy is effective in reducing left ventricular mass. 13 Nevertheless, a mild prevalence of LVH but a significant increase in levels of ISVTd in subjects with higher values of TGF␤1 have been found in the present study.
In conclusion, our data, indicated that TGF␤1 might be considered useful marker in evaluating the severity and progression of hypertensive renal disease. In view of this, hypertensive subjects with proteinuria and higher levels of TGF␤1 may be considered at a higher risk of ESRD. This hypothesis might better address the goal of the treatment in hypertensive renal disease. In fact, despite there being little clinical data on the beneficial effects, of directly targeting the TGF␤1 system, it is becoming clear that agents which inhibit the renin-angiotensin system reduce TGF␤1 expression in experimental models. According to some authors this inhibition has to be considered to define the major mechanism of the renoprotective effects of these drugs. 30 However, additional long-term clinical data are needed to evaluate whether inhibition of the TGF␤1 system may slow the progression of hypertensive renal disease and prolong the time to the ESRD.
